CGEN
Price
$1.47
Change
-$0.06 (-3.92%)
Updated
May 30 closing price
Capitalization
135.81M
59 days until earnings call
DTIL
Price
$4.83
Change
-$0.09 (-1.83%)
Updated
May 30 closing price
Capitalization
53.56M
Interact to see
Advertisement

CGEN vs DTIL

Header iconCGEN vs DTIL Comparison
Open Charts CGEN vs DTILBanner chart's image
Compugen
Price$1.47
Change-$0.06 (-3.92%)
Volume$77.66K
Capitalization135.81M
Precision BioSciences
Price$4.83
Change-$0.09 (-1.83%)
Volume$27.94K
Capitalization53.56M
CGEN vs DTIL Comparison Chart
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DTIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. DTIL commentary
Jun 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a StrongBuy and DTIL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 02, 2025
Stock price -- (CGEN: $1.47 vs. DTIL: $4.83)
Brand notoriety: CGEN and DTIL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 35% vs. DTIL: 20%
Market capitalization -- CGEN: $135.81M vs. DTIL: $53.56M
CGEN [@Biotechnology] is valued at $135.81M. DTIL’s [@Biotechnology] market capitalization is $53.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $307.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileDTIL’s FA Score has 0 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • DTIL’s FA Score: 0 green, 5 red.
According to our system of comparison, DTIL is a better buy in the long-term than CGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 6 TA indicator(s) are bullish while DTIL’s TA Score has 5 bullish TA indicator(s).

  • CGEN’s TA Score: 6 bullish, 3 bearish.
  • DTIL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CGEN is a better buy in the short-term than DTIL.

Price Growth

CGEN (@Biotechnology) experienced а +1.38% price change this week, while DTIL (@Biotechnology) price change was +5.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.39%. For the same industry, the average monthly price growth was +0.48%, and the average quarterly price growth was -5.03%.

Reported Earning Dates

CGEN is expected to report earnings on Jul 31, 2025.

DTIL is expected to report earnings on Mar 26, 2025.

Industries' Descriptions

@Biotechnology (+1.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($136M) has a higher market cap than DTIL($53.6M). CGEN has higher P/E ratio than DTIL: CGEN (64.00) vs DTIL (4.53). DTIL YTD gains are higher at: 26.772 vs. CGEN (-3.922). DTIL has higher annual earnings (EBITDA): 18.8M vs. CGEN (-14.41M). CGEN (103M) and DTIL (101M) have equal amount of cash in the bank . CGEN has less debt than DTIL: CGEN (2.91M) vs DTIL (30.3M). DTIL has higher revenues than CGEN: DTIL (75.1M) vs CGEN (27.9M).
CGENDTILCGEN / DTIL
Capitalization136M53.6M254%
EBITDA-14.41M18.8M-77%
Gain YTD-3.92226.772-15%
P/E Ratio64.004.531,413%
Revenue27.9M75.1M37%
Total Cash103M101M102%
Total Debt2.91M30.3M10%
FUNDAMENTALS RATINGS
CGEN vs DTIL: Fundamental Ratings
CGEN
DTIL
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9241
PRICE GROWTH RATING
1..100
8288
P/E GROWTH RATING
1..100
22100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DTIL's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for CGEN (77). This means that DTIL’s stock grew somewhat faster than CGEN’s over the last 12 months.

DTIL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CGEN (100). This means that DTIL’s stock grew similarly to CGEN’s over the last 12 months.

DTIL's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for CGEN (92). This means that DTIL’s stock grew somewhat faster than CGEN’s over the last 12 months.

CGEN's Price Growth Rating (82) in the Biotechnology industry is in the same range as DTIL (88). This means that CGEN’s stock grew similarly to DTIL’s over the last 12 months.

CGEN's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for DTIL (100). This means that CGEN’s stock grew significantly faster than DTIL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENDTIL
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
79%
MACD
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 27 days ago
89%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
72%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DTIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QCGDX14.520.06
+0.41%
Quantified Common Ground Investor
CSIIX8.580.01
+0.12%
Copeland International Small Cap I
MBINX30.720.03
+0.10%
NYLI Balanced Investor Class
MFWLX17.080.01
+0.06%
MFS Global Total Return R6
SVFFX72.11-0.21
-0.29%
Smead Value I1

CGEN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
-3.92%
NURPF - CGEN
46%
Loosely correlated
N/A
BDTX - CGEN
43%
Loosely correlated
-2.22%
ASPHF - CGEN
41%
Loosely correlated
N/A
ORMP - CGEN
40%
Loosely correlated
+4.93%
ARWR - CGEN
39%
Loosely correlated
-4.46%
More

DTIL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DTIL has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DTIL jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DTIL
1D Price
Change %
DTIL100%
-1.83%
AXON - DTIL
46%
Loosely correlated
+2.75%
ORMP - DTIL
41%
Loosely correlated
+4.93%
ARRY - DTIL
39%
Loosely correlated
-0.30%
RENB - DTIL
36%
Loosely correlated
-1.68%
GLYC - DTIL
35%
Loosely correlated
-1.55%
More